Article
Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.
International journal of laboratory hematology - 1 Feb 2010
Ma W, Kantarjian H, Zhang X, Yeh C-H, Zhang Z J, Verstovsek S, O'Brien S, Giles F, Albitar M
Abstract excerpt
The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). We found plasma levels of total JAK2 mRNA to be higher in patients with non-CML MPD (n=175) than in CML patients (n=45) and normal controls (n=58) (each P<0.001). Overall survival was studied in 68 patients and showed positive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.